Gyre Therapeutics (NASDAQ:GYRE) Shares Down 4.1%

Gyre Therapeutics, Inc. (NASDAQ:GYRE)’s stock price traded down 4.1% during mid-day trading on Wednesday . The stock traded as low as $15.26 and last traded at $15.35. 6,659 shares changed hands during mid-day trading, a decline of 92% from the average session volume of 83,339 shares. The stock had previously closed at $16.00.

Gyre Therapeutics Stock Down 2.7 %

The company’s 50-day moving average price is $17.31.

Institutional Investors Weigh In On Gyre Therapeutics

A hedge fund recently bought a new stake in Gyre Therapeutics stock. Vanguard Group Inc. bought a new position in shares of Gyre Therapeutics, Inc. (NASDAQ:GYRE) during the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm bought 198,097 shares of the company’s stock, valued at approximately $5,089,000. Vanguard Group Inc. owned approximately 7.82% of Gyre Therapeutics as of its most recent SEC filing. 23.99% of the stock is owned by hedge funds and other institutional investors.

About Gyre Therapeutics

Gyre Therapeutics, Inc, a biopharmaceutical company, primarily focuses on the development and commercialization of Hydronidone for the treatment of Metabolic Dysfunction Associated Steatohepatitis in the United States. Its Hydronidone is also being evaluated for the treatment of liver fibrosis across a spectrum of chronic liver diseases.